Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Hellmann

Showing results (141-150 of 172) with videos related to

Pageof 18
Sort By:
Cancer Research|February 3, 2016
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor MicroenvironmentShohei Koyama, Esra A Akbay, Yvonne Y Li, et al.
Cell|October 2, 2020
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint InhibitionBarzin Y Nabet, Mohammad S Esfahani, Everett J Moding, et al.
Cell|October 16, 2020
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder CancerPatrick A Ott, Siwen Hu-Lieskovan, Bartosz Chmielowski, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 27, 2022
Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung CancerSemanti Mukherjee, Chaitanya Bandlamudi, Matthew D Hellmann, et al.
The New England Journal of Medicine|April 17, 2018
Neoadjuvant PD-1 Blockade in Resectable Lung CancerPatrick M Forde, Jamie E Chaft, Kellie N Smith, et al.
Cancer Research|December 14, 2018
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung CancerValsamo Anagnostou, Patrick M Forde, James R White, et al.
Cancer Immunology Research|April 16, 2017
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLCPaul C Tumeh, Matthew D Hellmann, Omid Hamid, et al.
Science (New York, N.Y.)|March 5, 2016
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockadeNicholas McGranahan, Andrew J S Furness, Rachel Rosenthal, et al.
Immunity|December 27, 2022
The ectonucleotidase CD39 identifies tumor-reactive CD8<sup>+</sup> T cells predictive of immune checkpoint blockade efficacy in human lung cancerAndrew Chow, Fathema Z Uddin, Michael Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2021
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 TrialLuis G Paz-Ares, Suresh S Ramalingam, Tudor-Eliade Ciuleanu, et al.
Pageof 18

Showing results (141-150 of 172) with videos related to

Sort By:
Pageof 18
Cancer Research|February 3, 2016
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor MicroenvironmentShohei Koyama, Esra A Akbay, Yvonne Y Li, et al.
Cell|October 2, 2020
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint InhibitionBarzin Y Nabet, Mohammad S Esfahani, Everett J Moding, et al.
Cell|October 16, 2020
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder CancerPatrick A Ott, Siwen Hu-Lieskovan, Bartosz Chmielowski, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 27, 2022
Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung CancerSemanti Mukherjee, Chaitanya Bandlamudi, Matthew D Hellmann, et al.
The New England Journal of Medicine|April 17, 2018
Neoadjuvant PD-1 Blockade in Resectable Lung CancerPatrick M Forde, Jamie E Chaft, Kellie N Smith, et al.
Cancer Research|December 14, 2018
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung CancerValsamo Anagnostou, Patrick M Forde, James R White, et al.
Cancer Immunology Research|April 16, 2017
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLCPaul C Tumeh, Matthew D Hellmann, Omid Hamid, et al.
Science (New York, N.Y.)|March 5, 2016
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockadeNicholas McGranahan, Andrew J S Furness, Rachel Rosenthal, et al.
Immunity|December 27, 2022
The ectonucleotidase CD39 identifies tumor-reactive CD8<sup>+</sup> T cells predictive of immune checkpoint blockade efficacy in human lung cancerAndrew Chow, Fathema Z Uddin, Michael Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2021
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 TrialLuis G Paz-Ares, Suresh S Ramalingam, Tudor-Eliade Ciuleanu, et al.
Pageof 18